Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders

1. A method to modulate wound healing processes in a subject, said method comprising the administration of a composition containing an effective amount of a phosphonate prodrug of a phosphonotetrahydropyran compound of a compound of Formula I, and an acceptable pharmaceutical carrier,

wherein the phosphonate prodrug is a mono- or di-ester of the phosphonic acid functionality; and

wherein n is an integer from 0 to 3, the —O(CH 2 ) n R group is in an axial or equatorial position, and R is lower alkyl, or optionally substituted heteroaryl or optionally substituted aryl wherein the substituent is selected from the group consisting of —Cl, —F, CF 3 , CH 3 , CH 2 CH 3 , —OCH 3 , —OCF 3 , —(CH 2 ) m CO 2 R 1 , —(CH 2 ) m OR 2 , —(CH 2 ) m CONHR 2 , —(CH 2 ) m NHR 2 , and —(CH 2 ) m CONR 2 R 3 , wherein m is an integer from 0 to 3; R 1 is selected from the group of consisting of H, alkyl and aryl; and R 2 and R 3 are independently selected from the group consisting of H, alkyl, aryl and acyl.

2. The method of claim 1 where the subject has a disease or disorder associated with the deposition of excess collagen, fibronectin and or other extracellular matrix components.

3. The method of claim 2 where the disease or disorder is lung fibrosis, glaucoma, scleroderma, liver fibrosis, cardiac fibrosis, renal fibrosis or renal failure.

4. The method of claim 1 where wound healing process is subsequent to a surgical procedure.

5. The method of claim 4 where the surgical procedure involves eye surgery, is performed on internal organs and tissues, is performed on the epidermal layer or is a procedure to repair tendon injury.

6. The method of claim 5 where the surgical procedure is performed on the epidermal layer and may lead to keloid formation or is associated with cosmetic or plastic surgery.

7. The method of claim 1 where the composition is administered to the site of inflammation and wound healing.

8. The method of claim 7 where the composition is administered directly to the lung, or to the eye.

9. A method of treating pulmonary fibrosis, comprising administering to a subject in need of treatment, an effective amount of a composition comprising a phosphonate prodrug of a phosphonotetrahydropyran compound of Formula I:

wherein the phosphonate prodrug is a mono- or di-ester of the phosphonic acid functionality; and

wherein n is an integer from 0 to 3, the —O(CH 2 ) n R group is in an axial or equatorial position, and R is lower alkyl, or optionally substituted heteroaryl or optionally substituted aryl wherein the substituent is selected from the group consisting of —Cl, —F, CF 3 , CH 3 , CH 2 CH 3 , —OCH 3 , —OCF 3 , —(CH 2 ) m CO 2 R 1 , —(CH 2 ) m OR 2 , —(CH 2 ) m CONHR 2 , —(CH 2 ) m NHR 2 , and —(CH 2 ) m CONR 2 R 3 , wherein m is an integer from 0 to 3; R 1 is selected from the group of consisting of H, alkyl and aryl; and R 2 and R 3 are independently selected from the group consisting of H, alkyl, aryl and acyl.

10. The method of claim 9 , wherein the subject suffers from idiopathic pulmonary fibrosis or other fibrotic disorders of the lung.

11. The method of claim 9 wherein the phosphonate prodrug is co-administered with a compound selected from the group consisting of N-acetyl cysteine, aminoguanidine, anti-VEGF antibody, Batimastat, Bosentan, dexamethasone, difluoromethylornithine, Etanercept, Gefitinib, Imatinib, methylprednisolone, Pentoxifylline, Pirfenidone, prednisolone, Rosiglitazone, TGF-beta antibody, TNF-alpha antibody, and Vinblastine.

12. The method of claim 1 wherein the phosphonate prodrug is selected from the group consisting of:

wherein X is a hydrogen or substituted alkyl and Px is alkyl.

13. The method of claim 1 wherein the subject is a human.

14. A pharmaceutical composition for modulating wound healing processes or treating pulmonary fibrosis in a subject, comprising a phosphonate prodrug of a phosphonotetrahydropyran compound of a compound of Formula I:

and an acceptable pharmaceutical carrier

wherein the phosphonate prodrug is a mono- or di-ester of the phosphonic acid functionality; and

wherein n is an integer from 0 to 3, the —O(CH 2 ) n R group is in an axial or equatorial position, and R is lower alkyl, or optionally substituted heteroaryl or optionally substituted aryl wherein the substituent is selected from the group consisting of —Cl, —F, CF 3 , CH 3 , CH 2 CH 3 , —OCH 3 , —OCF 3 , —(CH 2 ) m CO 2 R 1 , —(CH 2 ) m OR 2 , —(CH 2 ) m CONHR 2 , —(CH 2 ) m NHR 2 , and —(CH 2 ) m CONR 2 R 3 , wherein m is an integer from 0 to 3; R 1 is selected from the group of consisting of H, alkyl and aryl; and R 2 and R 3 are independently selected from the group consisting of H, alkyl, aryl and acyl.

15. The pharmaceutical composition of claim 14 wherein the phosphonate prodrug is selected from the group consisting of:

wherein X is a hydrogen or substituted alkyl and Px is alkyl.

16. The pharmaceutical composition of claim 15 wherein phosphonate prodrug is selected from the group consisting of:

17. The pharmaceutical composition of claim 14 , wherein the composition is for treating pulmonary fibrosis and further comprises a compound selected from the group consisting of N-acetyl cysteine, aminoguanidine, anti-VEGF antibody, Batimastat, Bosentan, dexamethasone, difluoromethylornithine, Etanercept, Gefitinib, Imatinib, methylprednisolone, Pentoxifylline, Pirfenidone, prednisolone, Rosiglitazone, TGF-beta antibody, TNF-alpha antibody, and Vinblastine.

18. The method of claim 12 wherein phosphonate prodrug is selected from the group consisting of:

19. The method of claim 9 wherein the prodrug is selected from the group consisting of:

wherein X is a hydrogen or substituted alkyl and Px is alkyl.

20. The method of claim 19 wherein the phosphonate prodrug is selected from the group consisting of: